Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, September 29, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding D.R. Horton Inc. (NYSE: DHI), Mallinckrodt PLC (NYSE: MNK), Illumina Inc. (NASDAQ: ILMN), Ventas, Inc. (NYSE: VTR) and Capital One Financial Corporation (NYSE: COF). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6815-100free.
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
Company Background
Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. On June 28, 2013, Covidien plc completed the separation of its Pharmaceuticals business and transferred the Pharmaceuticals business to Mallinckrodt. In March 2014, the Company acquired Cadence Pharmaceuticals, Inc. In August 2014, Mallinckrodt Plc acquired Questcor Pharmaceuticals, Inc. On August 15, 2014, Lucio Co, through VFC Land Resources Inc, acquired 3.092% interest in Makati-based Philippine Bank of Communications.